SG10201810449XA - Organoarsenic compounds and methods for the treatment of cancer - Google Patents

Organoarsenic compounds and methods for the treatment of cancer

Info

Publication number
SG10201810449XA
SG10201810449XA SG10201810449XA SG10201810449XA SG10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA SG 10201810449X A SG10201810449X A SG 10201810449XA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
methods
organoarsenic compounds
organoarsenic
Prior art date
Application number
SG10201810449XA
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Solasia Pharma K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solasia Pharma K K filed Critical Solasia Pharma K K
Publication of SG10201810449XA publication Critical patent/SG10201810449XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

OrganoarsenicCompounds And Methods For The Treatment Of Cancer A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and Rl and R are independently Cl-30alkyl (R3, R3', R4, R5, W and "n" are as defined in claim 1 ) in particular where the compound is S- dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2- amino-3- (dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S- dipropylarsino-1 - thioglycerol. (I) W -41-
SG10201810449XA 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer SG10201810449XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
SG10201810449XA true SG10201810449XA (en) 2018-12-28

Family

ID=41707414

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Country Status (19)

Country Link
US (4) US20110269697A1 (en)
EP (2) EP2321012B1 (en)
JP (5) JP5933896B2 (en)
KR (3) KR20170103023A (en)
CN (2) CN102149432A (en)
AU (1) AU2009282972A1 (en)
BR (1) BRPI0918407A2 (en)
CA (1) CA2734650A1 (en)
DK (2) DK2321012T3 (en)
ES (2) ES2703740T3 (en)
HK (2) HK1254607A1 (en)
IL (1) IL211153A0 (en)
MX (1) MX2011001800A (en)
NZ (1) NZ591181A (en)
PT (2) PT3388111T (en)
RU (1) RU2534606C2 (en)
SG (3) SG10201810449XA (en)
WO (1) WO2010021928A1 (en)
ZA (1) ZA201101216B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085208A1 (en) * 2013-12-05 2015-06-11 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN104151397A (en) * 2014-07-03 2014-11-19 北京大学 Novel thiabicyclo organic arsenide compound and synthesis method thereof, as well as application in anti-tumor field
JP6413969B2 (en) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 Dispersion for forming solar shading body and solar shading body using the dispersion
JPWO2019220961A1 (en) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 Crystalline form of darinaparcin alkali metal salt and/or inorganic acid addition salt and preparation thereof
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (en) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 Method and device for detecting purity of flue-cured tobacco, electronic equipment and storage medium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
DK1378240T3 (en) 1997-10-15 2008-12-08 Polarx Biopharmaceuticals Inc Pharmaceutical compositions comprising arsenic trioxide for the treatment of multiple myeloma
ES2399480T3 (en) 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Production process of arsenic trioxide formulations
CN1233476A (en) 1998-04-24 1999-11-03 陆道培 Medicine for treating acute leukemia, and method for preparing same
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
BR0110403A (en) 2000-04-26 2004-02-25 Univ Oregon Health Sciences Administration of a thiol-based chemoprotective compound
DE10132625A1 (en) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Process, computer program product and device system for visually checking image data
EP2420229A1 (en) 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201350113A (en) 2004-07-16 2013-12-16 Texas A & M Univ Sys Organic arsenic compounds, uses of the same in treating cancer and pharmaceutical compositions comprising the same
WO2007027344A2 (en) 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
WO2007082104A2 (en) * 2006-01-13 2007-07-19 The Texas A & M University System Compounds and methods for the treatment of cancer
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
AU2008276455A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Combinations for the treatment of B-cell proliferative disorders
EP2178369A4 (en) * 2007-07-17 2010-12-15 Combinatorx Inc Treatments of b-cell proliferative disorders
AU2008325243B2 (en) * 2007-11-02 2014-07-03 Solasia Pharma K.K. Combination therapy with organic arsenicals
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
BRPI0918407A2 (en) 2015-11-24
AU2009282972A1 (en) 2010-02-25
US20210038556A1 (en) 2021-02-11
PT3388111T (en) 2021-12-23
EP3388111A1 (en) 2018-10-17
IL211153A0 (en) 2011-04-28
EP2321012A4 (en) 2011-10-05
PT2321012T (en) 2019-01-11
US20110269697A1 (en) 2011-11-03
JP2012500271A (en) 2012-01-05
US10842769B2 (en) 2020-11-24
US11324714B2 (en) 2022-05-10
JP5933896B2 (en) 2016-06-15
JP5976036B2 (en) 2016-08-23
DK2321012T3 (en) 2018-12-03
JP2017002081A (en) 2017-01-05
KR20170103023A (en) 2017-09-12
KR20180103194A (en) 2018-09-18
US20150231107A1 (en) 2015-08-20
CA2734650A1 (en) 2010-02-25
SG10201810450QA (en) 2018-12-28
CN102149432A (en) 2011-08-10
SG10201403869TA (en) 2014-10-30
JP2015120755A (en) 2015-07-02
RU2534606C2 (en) 2014-11-27
ES2901426T3 (en) 2022-03-22
EP2321012A1 (en) 2011-05-18
JP2014148552A (en) 2014-08-21
US20210038557A1 (en) 2021-02-11
HK1212218A1 (en) 2016-06-10
ES2703740T3 (en) 2019-03-12
CN104800828A (en) 2015-07-29
ZA201101216B (en) 2011-10-26
WO2010021928A1 (en) 2010-02-25
US11324713B2 (en) 2022-05-10
KR20110058818A (en) 2011-06-01
NZ591181A (en) 2012-09-28
JP6315841B2 (en) 2018-04-25
EP3388111B1 (en) 2021-09-29
HK1254607A1 (en) 2019-07-26
EP2321012B1 (en) 2018-10-10
MX2011001800A (en) 2011-04-04
JP2018039853A (en) 2018-03-15
RU2011110392A (en) 2012-09-27
DK3388111T3 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
SG10201810450QA (en) Organoarsenic compounds and methods for the treatment of cancer
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MX2009005649A (en) Treatment for multiple myeloma.
TW200744586A (en) Therapeutic compounds
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
MXPA05009694A (en) Methods of improving skin quality.
BRPI0413746A (en) compound or a n-oxide thereof or pharmaceutically acceptable salt thereof, composition, and method of treating hyperproliferative disorder
NZ580226A (en) Dimer compounds as inhibitors of iap
GEP20125643B (en) Aurora kinase modulators and method of using same
TW200732341A (en) Chemical compounds
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
EA201000895A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIZOSOME DISEASES
BRPI0413740A (en) compound or a n-oxide thereof or pharmaceutically acceptable salt thereof, composition, and method of treating hyperproliferative disorder
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
TW200510317A (en) Caspase inhibitors and uses thereof
TW200613292A (en) Benzothiazolium compounds
MX2010008226A (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension.
UA107562C2 (en) METHOD OF TREATMENT OF PSORIASIS
EA200701852A1 (en) DERIVATIVES OF AMINO ACIDS
EA201170344A1 (en) AZAINDOL IAP INHIBITORS
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
WO2004033423A3 (en) Anticancer compounds
TW200600084A (en) Anti-coronavirus compounds
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor